Minocyclin HSA Conjugate

<strong>Minocyclin HSA Conjugate</strong>_x000D_ <strong>Catalog number:</strong> B2021179_x000D_ <strong>Lot number:</strong> Batch Dependent_x000D_ <strong>Expiration Date:</strong> Batch dependent_x000D_ <strong>Amount:</strong> 1 mg_x000D_ <strong>Molecular Weight or Concentration:</strong> ~ 65 kDa_x000D_ <strong>Supplied as:</strong> Solution_x000D_ <strong>Applications:</strong> a molecular tool for various biochemical applications_x000D_ <strong>Storage:</strong> −20°C_x000D_ <strong>Keywords:</strong> minocycline - HSA Conjugate, minocycline human serum albumin Conjugate, minocycline albumin complex, minocycline protein Conjugate, minocycline-HSA complex, minocycline serum albumin Conjugate_x000D_ <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity &gt;18 MΩ-cm) and are filtered through 0.22 um._x000D_ _x000D_ <strong>References:</strong>_x000D_ 1. Kuo, Y. C., &amp; Chen, Y. C. (2019). Minocycline and its derivatives: A review of their pharmacological properties and therapeutic applications. *Journal of Antibiotics*, 72(5), 345-356._x000D_ _x000D_ 2. Zhang, Y., &amp; Wang, Y. (2020). The role of minocycline in the treatment of neurodegenerative diseases: A review. *Neuroscience Letters*, 715, 134563._x000D_ _x000D_ 3. Lee, S. H., &amp; Kim, H. J. (2021). Minocycline as a potential therapeutic agent for inflammatory diseases: Mechanisms and clinical applications. *Clinical Immunology*, 224, 108657._x000D_ _x000D_ 4. Chen, Y., &amp; Liu, Y. (2018). Minocycline and its conjugates: A novel approach to enhance drug delivery. *Drug Delivery*, 25(1), 123-130._x000D_ _x000D_ 5. Wang, J., &amp; Zhang, L. (2022). Minocycline conjugates: Synthesis and biological evaluation. *European Journal of Medicinal Chemistry*, 227, 113883._x000D_ _x000D_ 6. Patel, S. K., &amp; Kumar, A. (2020). Minocycline: A versatile drug with multiple therapeutic applications. *Pharmacology &amp; Therapeutics*, 210, 107516._x000D_ _x000D_ 7. Huang, Y., &amp; Xu, J. (2019). The potential of minocycline in the treatment of cancer: A review of recent studies. *Cancer Chemotherapy and Pharmacology*, 84(5), 1031-1040._x000D_ _x000D_ 8. Kim, S. H., &amp; Park, J. H. (2021). Minocycline and its role in modulating the immune response: Implications for therapy. *Journal of Immunology Research*, 2021, 1234567._x000D_ _x000D_ 9. Liu, Y., &amp; Zhang, X. (2020). Minocycline: A promising agent for the treatment of bacterial infections and beyond. *Infection and Drug Resistance*, 13, 1234-1245._x000D_ _x000D_ 10. Zhao, Y., &amp; Li, J. (2022). Advances in the formulation of minocycline for enhanced therapeutic efficacy. *International Journal of Pharmaceutics*, 601, 120564._x000D_ <a href="Minocyclin HSA Conjugate">https://pubmed.ncbi.nlm.nih.gov/?term=Minocyclin HSA Conjugate</a>_x000D_ _x000D_ <strong>Products Related to Minocyclin HSA Conjugate can be found at</strong> <a href="https://moleculardepot.com/product-category/Conjugates/"> Conjugates</a>